<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140437</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2014-14</org_study_id>
    <nct_id>NCT02140437</nct_id>
  </id_info>
  <brief_title>Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC</brief_title>
  <official_title>An Open-label, Multi-center, Randomized Phase II Study of Fulvestrant Anastrozole Combination Versus Anastrozole Alone in Patients With Luminal A-like Postmenopausal Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is designed to investigate whether the addition of fulvestrant 500mg to&#xD;
      anastrozole is better than anastrozole alone as first-line endocrine therapy for advanced&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anastrozole is the standard first-line endocrine treatment for patients with hormonal&#xD;
      receptor positive advanced breast cancer. It has been proven that the addition of fulvestrant&#xD;
      250mg can enhance PFS of anastrozole monotherapy according to SWOG0226 study. However, the&#xD;
      optimal recommended dose of fulvestrant for patients with advanced breast cancer is 500mg&#xD;
      worldwide according to CONFIRM study. The investigator designed this research to investigate&#xD;
      whether high dose fulvestrant can further improve efficacy of anastrozole monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The progress of enrollment is too slow.&#xD;
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS(Progression free survival)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS(overall survival )</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>ORR(objective response rate)</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CBR(Clinical benefit rate)</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with grade 3 or 4 adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Carcinoma Breast Stage IV</condition>
  <arm_group>
    <arm_group_label>Fulvestrant and anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole 1 mg PO QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Adding fulvestrant to the standard endocrine therapy, anastrozole</description>
    <arm_group_label>Fulvestrant and anastrozole</arm_group_label>
    <other_name>falsodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>standard endocrine therapy</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_label>Fulvestrant and anastrozole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Histologically confirmed breast cancer&#xD;
&#xD;
          3. Luminal A-like breast cancer (primary or metastatic tumor), defined as: ER-positive,&#xD;
             PR-positive (&gt; 20%), Her-2 negative and Ki67 &lt;14%.&#xD;
&#xD;
          4. Advanced breast cancer is eligible:&#xD;
&#xD;
               -  Endocrine therapy-naive patients with locally advanced disease, who are not&#xD;
                  suitable for radical surgery or radiotherapy (the decision made by the&#xD;
                  multidisciplinary breast cancer team). Prior first-line cytotoxic chemotherapy is&#xD;
                  acceptable. or&#xD;
&#xD;
               -  Patients with recurrent or metastatic disease, who have not received adjuvant&#xD;
                  endocrine therapy or who have been 2 years or longer after stop of adjuvant&#xD;
                  endocrine therapy. Patients who had disease progression from first-line cytotoxic&#xD;
                  chemotherapy are allowed.&#xD;
&#xD;
          5. At least one lesion (measurable and / or non-measurable) can be assessed at baseline,&#xD;
             and is suitable for repeated assessments with CT and/or MRI.&#xD;
&#xD;
          6. Postmenopausal women, defined as any one of the following criteria (as defined in the&#xD;
             NCCN's menopause definition):&#xD;
&#xD;
               -  previous bilateral oophorectomy&#xD;
&#xD;
               -  60 years old or older&#xD;
&#xD;
               -  less than 60 years old, amenorrheic for 12 months or longer in the absence of&#xD;
                  chemotherapy, tamoxifen, toremifene, or ovarian suppression and&#xD;
                  follicle-stimulating hormone and estradiol in the postmenopausal range.&#xD;
&#xD;
               -  If taking tamoxifen, or toremifene and age &lt; 60, then FSH and E in the&#xD;
                  postmenopausal range&#xD;
&#xD;
          7. ECOG 0, 1 or 2.&#xD;
&#xD;
          8. Patients with good compliance.&#xD;
&#xD;
          9. Must be able to swallow tablets.&#xD;
&#xD;
         10. Without any significant gastrointestinal obstruction or dysfunction of absorption for&#xD;
             oral drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life-threatening metastatic visceral disease, defined as extensive liver involvement&#xD;
             or any degree of brain or leptomeningeal involvement (past or present) or symptomatic&#xD;
             pulmonary lymphatic metastasis. If the investigator believe that their respiratory&#xD;
             function is not significantly impaired due to illness, patients with scattered&#xD;
             parenchymal metastases are qualified.&#xD;
&#xD;
          2. Have received any systemic treatment other than first-line cytotoxic chemotherapy.&#xD;
&#xD;
          3. Radiation therapy within 28 days prior to randomization (exception: radiotherapy to&#xD;
             control bone pain, but should be completed before the randomization).&#xD;
&#xD;
          4. Use any other anti-cancer therapy at the same time (except bisphosphonate).&#xD;
&#xD;
          5. Previous endocrine treatment for advanced breast cancer.&#xD;
&#xD;
          6. Current or previous malignancy ( except for breast cancer, basal cell or squamous cell&#xD;
             carcinoma of the skin with adequate treatment, cervical carcinoma in situ).&#xD;
&#xD;
          7. Inadequate blood or liver or renal function within one week prior to randomization:&#xD;
             Platelets &lt; 80 × 10^9/L; Total bilirubin &gt; 1.5 × (ULRR) (patients with Gilbert's&#xD;
             syndrome is eligible); or ALT or AST &gt; 2.5 × ULRR (without liver metastases) or &gt; 5 ×&#xD;
             ULRR (with liver metastases).&#xD;
&#xD;
          8. History with hemorrhagic constitution (e.g. disseminated intravascular coagulation,&#xD;
             clotting factor deficiency) or long-term anticoagulant therapy.&#xD;
&#xD;
          9. Hypersensitivity history to excipients or castor oil of fulvestrant or anastrozole.&#xD;
&#xD;
         10. Any other severe co-existing medical disorders, ie uncontrolled heart disease.&#xD;
&#xD;
         11. Participation in any clinical trial and / or exposure to any investigational&#xD;
             medication within 28 days before randomization.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>December 24, 2015</last_update_submitted>
  <last_update_submitted_qc>December 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>M.D. Ph. D.</investigator_title>
  </responsible_party>
  <keyword>Fulvestrant</keyword>
  <keyword>Anastrozole</keyword>
  <keyword>Luminal A-like</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Advanced breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

